FDA Expands Mounjaro Approval to Reduce Cardiovascular Risk in Type 2 Diabetes
The FDA approved Mounjaro (tirzepatide) to reduce major adverse cardiovascular events — cardiovascular death, nonfatal heart attack, and nonfatal stroke — in adults with type 2 diabetes at high cardiovascular risk. The approval follows the Surpass-CVOT trial involving over 13,000 participants across 30 countries. The expanded indication is effective immediately. This matters for Medicaid managed care organizations because cardiovascular disease is a leading driver of costs in diabetic populations, and the new indication may affect prior authorization policies, formulary placement, and utilization management for tirzepatide in high-risk beneficiaries.
Expanded cardiovascular indications for high-cost GLP-1 medications will intensify formulary and prior authorization decisions for Medicaid health plans managing diabetic populations with comorbidities.
Pharmacy · Managed Care
You might also like